Vir Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2020 Annual Meeting of Stockholders held by Vir Biotechnology, Inc. on May 20, 2020. The record date for the meeting was March 27, 2020, with 109,803,505 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Proposal 1: Election of Directors - Three Class I Directors were elected to serve until the 2023 Annual Meeting.
- Kristina Burow: 62,514,147 votes for; 363,745 votes withheld.
- Robert More: 62,754,101 votes for; 123,791 votes withheld.
- Vicki Sato, Ph.D.: 62,606,467 votes for; 271,425 votes withheld.
- Proposal 2: Ratification of Independent Auditor - Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Votes For: 63,862,989
- Votes Against: 28,183
- Abstentions: 27,418
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that the three Class I Directors (Burow, More, Sato) were successfully elected.
- Verification that Ernst & Young LLP was ratified as the auditor for the 2020 fiscal year.
- Review of the total shares outstanding (109,803,505) to assess voting participation rates.